Вы находитесь на странице: 1из 1

Medizinische

EUROIMMUN Labordiagnostika
AG

Strategy for Determination of Autoantibodies against Cell Nuclei (ANA) and Cytoplasm Components
Screening test (indirect immunofluorescence) Human epithelial cells (HEp-2) and primate liver

Cell nuclei, homogen. Cell nuclei, peripheral Nucleoplasm, dotted Nucleoplasm, granular
Interphase: homogeneous Nuclear membrane HEp-2: 46 / 92 dots HEp-2: 6 - 20 dots HEp-2: 2 - 6 dots Granular with HEp-2: fine granular, nucleoli pos. HEp-2: granular HEp-2: coarse granular Different degrees Different degrees
granular chromo- of reactivity, of reactivity.
Chromosome bands: positive positive Liver: weak reaction Liver: several dots Liver: positive or negative some bands or neg. liver: weak fluorescence Liver: clumpy, granular Liver: strong fluorescence mitotic cells neg. mitotic cells pos.

AC-1 AC-11/AC-12 AC-3 AC-6 AC-7 AC-2 AC-4 AC-4 AC-5 AC-13 AC-14

ANA pattern homogeneous Anti-DFS Pattern Pattern


AAb against nuclear membrane Anti-centromeres ANA pattern Nuclear Dots ANA pattern Few Nuclear Dots Anti-SS-A/SS-B Anti-Ku Anti-nRNP/Sm
PCNA-like CENP-F-like
SLE, drug- various various
PBC PSS, lim. Other rheumatic diseases SjS, SLE SjS, SLE, NLE SLE, PSS, diff., PM, DM SLE, MCTD
induced lupus, JIA diseases SLE malignoma

IFT: Crithidia luciliae (Anti-dsDNA) ELISA: Anti- ELISA: ANA Screen, Anti-ENA ELISA: ANA Screen, Anti-ENA ELISA: ANA
ELISA: ANA Screen, Anti-ENA EUROLINE: Profiles ANA, DFS70 Profiles, Anti-SS-A / B Profiles, Anti-nRNP / Sm Screen Profiles
ELISA: Anti-dsDNA, -histones, EUROLINE: Profiles ANA, liver ProfilePlus 2, Anti-centromeres EUROLINE: Profiles ANA, EUROLINE:
liver diseases EUROLINE:
-nucleosomes diseases (Anti-gp210) EUROLINE: Profiles ANA, myositis, systemic sclerosis EUROLINE: Profiles ANA, EUROLINE:
EUROLINE: Profiles (Anti-CENP B) (Anti-Sp100, -PML) ANA Profiles,
RIA: Anti-dsDNA Anti-DFS70 Anti-ENA, liver diseases Anti-ENA ANA Profiles

Nucleoli positive Cytoplasm filamentous Cytoplasm homogeneous Systemic lupus erythematosus Progressive systemic sclerosis (diff. form)
Autoantibodies against Prevalence Autoantibodies against Prevalence
Nucleoli stressed, Nucleoli Nucleoli Nucleoli Nucleoli granular, HEp-2: Needle-shaped fibre HEp-2 and liver: fine fibres. HEp-2: Fibre slings. Double-stranded DNA(dsDNA) 60 – 90 % Fibrillarin (U3-nRNP) 5 – 10 %
nucleoplasm mitotic cells: Homogeneous Homogeneous Single-stranded DNA (ssDNA) 70 – 95 % Scl-1 (75-kDa- / 13 %
homogeneous homogeneous fine granular coarse granular single dots bundles. Liver: Bile canaliculi Droplets in the mitotic cells Liver: Fibres in the parenchyma
100-kDa-main antigen) (10 % / 7 %)
Nucleosomes 50 – 70 %
Scl-70 25 – 75 %
RNA 50 %
RNA-polymerase I 4%
RNA-helicase A 6%
Ku, incl. overlap syndrome
Histones 50 – 80 % 25 – 50 %
with PM / DM
U1-nRNP 15 – 40 % NOR (NOR-90) rare
Sm 5 – 40 % 7 - 2-RNP (ThTo) rare
SS-A (Ro) 20 – 60 % Ro-52 28 %
SS-B (La) 10 – 20 %
Rheumatoid arthritis
AC-8 AC-9 AC-10 AC-10 AC-15 AC-16 AC-17 AC-19 AC-19 PCNA-like 3%
Autoantibodies against Prevalence
Ku 10 %
Anti-ribosomal Histones 15 – 50 %
Anti-Scl-70 Anti-PM-Scl Anti-fibrillarin Anti-RNA poly- Anti-NOR Anti-actin Anti-vimentin Anti-tropomyosin Anti-PL-7 / PL-12 Ribosomal P proteins 10 %
merase I P-proteins Single-stranded DNA 8%
Ro-52 38 %
PSS, diff. PM, DM, PSS, diff. PSS, diff. PSS, diff. PSS, diff. AIH Infections and inflammations Myastenia gravis, CU, MC SLE PM, DM (Cardiolipin 40 – 60 %)
U1-nRNP 3%
Ro-52 5%
Drug-induced lupus
ELISA: Profiles, ELISA: ANA Screen Profiles, EUROLINE: EUROLINE: ELISA: Profiles, Inclusion body myositis
EUROLINE: Autoantibodies against Prevalence
Anti-Scl-70 Anti-PM-Scl Profiles ANA, Profile Anti-rib. EUROLINE: Autoantibodies against Prevalence
Profile systemic P-proteins Histones 95 %
EUROLINE: EUROLINE: Profiles ANA, systemic sclerosis systemic Myositis Profiles cN-1A 39 %
sclerosis EUROLINE:
Profiles myositis, systemic sclerosis (Anti-RP11 / RP155) sclerosis Profiles Neonatal lupus erythematosus
Polymyositis and dermatomyositis
Autoantibodies against Prevalence
SS-A 100 % Autoantibodies against Prevalence
PM-Scl (PM-1), incl. overlap
HEp-2: mitotic cells positive Cytoplasm granular Primary Sjögren’s syndrome syndrome with PSS
24 – 55 %

Autoantibodies against Prevalence Jo-1 (Histidyl-tRNS-


Spindle apparatus 25 – 35 %
Spindle poles Spindle apparatus Cond. chromo- HEp-2 and liver: cytoplasm HEp-2: coarse granular HEp-2 cells: perinuclear Filamentous synthetase)
pos., inter-phase Midbody positive Fine granular SS-A (Ro) 40 – 95 %
positive positive cells: granular somes positive granular or drop-shaped Liver: positive Liver: positive structures Mi-1 10 %
SS-B (La) 40 – 95 %
Mi-2 5 – 30 %
Single-stranded DNA 13 %
Ku, incl. overlap syndrome
Ro-52 81 % 25 – 50 %
with PSS
(Salivary gland excretory Single-stranded DNA 40 – 50 %
40 – 60 %)
ducts
SRP 5%
Mixed connective tissue disease (MCTD, TIF1-gamma 5%
Sharp's syndrome). PL-7, PL-12 (aminoacyl-tRNS-
3–4%
Autoantibodies against Prevalence synthetases)
U1-nRNP 95 – 100 % Ro-52 30 %
AC-24 AC-25 AC-26 AC-27 AC-28 AC-18 AC-20 AC-21 AC-22 AC-23
Single-stranded DNA 20 – 50 % Autoimmune hepatitis
Pattern Pattern Pattern Pattern Anti-MCA Pattern “Rings Ro-52 19 % Autoantibodies against Prevalence
Anti-lysosomes Anti-Jo-1 Pattern AMA-like Anti-Golgi apparatus
Centrosomes MSA-2 NuMA-like Midbody & Rods“ ASMA (type F-actin) 40 – 90%
Raynaud syndr., SjS., rheum. SjS, arthritis, Raynaud syndr., PMR, DLE, Hepatitis C virus Primary biliary cirrhosis
PBC, neurol. diseases PM PBC SjS, SLE, RA ANA (lamines, SS-A, and
PSS, infections diseases APS, SLE malignoma, PSS SjS, CLL infection Autoantibodies against Prevalence 30 – 40 %
other)
Nuclear dots 25 – 40 % Liver kidney microsomes
IFT: Rat kidney / M2 7%
ELISA: Profiles, Nuclear membrane 20 – 40 % (LKM-1)
Anti-Jo-1 ELISA: Anti-M2, -M4, -M9 SS-A 20 % LC1 5%
AC = anti-cell pattern = Competent level according to ICAP
EUROLINE: EUROLINE: Profiles AMA, Centromeres 20 – 30 % Soluble liver antigen /Liver
10 – 30 %
ICAP: Internat. Consensus on Antinuclear Antibody Pattern (Chan et al. Report of the first international consensus on stan- = Expert level according to ICAP
Profiles ANA, liver pancreatic antigen (SLA/LP)
dardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015, ICAP. Front Immunol. 2015 Aug 20;6:412.) Ro-52 27 %
The additional use of BIOCHIPs with liver Liver membrane antigen
AAb: Autoantibodies AIH: Autoimmune hepatitis APS: Anti-phospholipid syndrome CFS: “Chronic fatigue M2 95 % 35 – 100 %
tissue may facilitate the pattern evaluation (LMA)
syndrome“ CLL: Chronic lymphatic leukaemia CU: Colitis ulcerosa DLE: Discoid lupus erythematosus
DM: Dermatomyositis HEp-2: Human Epithelial cells (HEp) JIA: Juvenile idiopathic arthritis NLE: Neonatal Liver-specific protein (LSP) 50 – 100 %
EUROLINE Profiles: ANA, cytoplasm, systemic sclerosis, liver diseases, myositis-ass. antigens Progressive systemic sclerosis (lim. form)
lupus erythematodes MC: Crohn’s disease MCTD: Mixed connective tissue disease, Sharp syndrome PBC: Primary
Asialoglycoprotein receptor
biliary cholangitis (liver cirrhosis) PM: Polymyositis PMR: Polymyalgia rheumatica PSS, diff.: Progressive systemic AAb against: nRNP/Sm, Sm, SS-A, SS-B, Ro-52, Scl-70, Jo-1, CENP A, CENP B, PCNA, dsDNA, nucleosomes, DFS70, histones, rib. P-Prot., Mi-2α, Mi-2β, TIF1γ, MDA5, NXP2, Autoantibodies against Prevalence 80 – 90%
protein
sclerosis, diffuse form PSS, lim.: Progressive systemic sclerosis, limited form RA: Rheumatoid arthritis SLE: Sys- SAE1, PM-Scl75/100, Ku, SRP, PL-7, PL-12, EJ, OJ, RP11, RP155, fibrillarin, NOR-90, Th/To, PDGFR, AMA-M2, M2-3E (BPO), Sp100, PML, gp210, LKM-1, LC-1, SLA/LP, PGDH
temic lupus erythematosus SjS: Sjögren’s syndrome Centromeres 80 – 95 % Ro-52 35 %

EUROIMMUN AG · 23560 Lübeck · Seekamp 31 Telephone +49 451 5855 0 · Telefax +49 451 5855 591 · euroimmun@euroimmun.de · www.euroimmun.de
HA_1500_I_UK_B09, 07 / 2017

Вам также может понравиться